Last Updated : August 19, 2019
Details
FilesGeneric Name:
Brigatinib
Project Status:
Complete
Therapeutic Area:
NSCLC
Manufacturer:
Takeda Canada Inc.
Brand Name:
Alunbrig
Project Line:
Reimbursement Review
Project Number:
PC0167-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
30 mg, 90 mg, and 180 mg
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (NSCLC)
Funding Request:
For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non–small cell lung cancer (NSCLC) who have progressed on or who were intolerant to an ALK inhibitor (crizotinib).
Sponsor:
Takeda Canada Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : August 19, 2019